Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
The companies announced they have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
